Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
CORCEPT THERAPEUTICS INC (CORT) reported that officer Sean Maduck exercised options for 25,000 shares of common stock on September 1, 2026 at an exercise price of $8.27 per share, then sold 25,000 shares the same day in multiple trades around $114–$116 per share under a Rule 10b5-1 trading plan. He also had 117 shares of common stock withheld on September 2, 2026 to cover tax obligations related to vesting restricted stock units and acquired small additional amounts of stock through a purchase plan and restricted stock awards.
CORCEPT THERAPEUTICS INC (CORT) reported that its Chief Financial Officer, Atabak Mokari, had routine equity-related transactions. On September 1, 2026, he acquired 138 shares of common stock under a purchase plan at a price based on the closing price that day and also received 138 shares underlying unvested restricted stock awards that will vest after one year if he remains the beneficial owner of the purchase-plan shares. On September 2, 2026, 102 shares of common stock were withheld to satisfy tax withholding obligations related to the vesting of restricted stock units; no Rule 10b5-1 trading plan is reported.
CORCEPT THERAPEUTICS INC (CORT) reported insider equity activity by Chief Business Officer Gary Charles Robb. On September 1, 2026, he acquired 164 shares of common stock through a purchase plan and a further 164 shares underlying restricted stock awards, which vest after one year if specified conditions are met. On September 2, 2026, 91 shares were withheld by the company to satisfy tax withholding obligations upon vesting of restricted stock units. He also reports indirect ownership of 39,716 shares held in a revocable trust, plus additional shares in custodial accounts for his children.
CORCEPT THERAPEUTICS INC (CORT) reported that President, Oncology Roberto Wandenkolk Vieira exercised stock options for 58,333 shares of common stock at $21.63 per share on September 2, 2026, then sold 58,333 shares in multiple open-market transactions and had 102 shares withheld to satisfy tax obligations. These sales were made under a Rule 10b5-1 trading plan adopted on June 17, 2026. On September 1, 2026 he also acquired 138 shares through a purchase plan and 138 restricted shares that vest after one year.
CORCEPT THERAPEUTICS INC (CORT) reported that Chief Accounting & Technology Officer Joseph Douglas Lyon had several equity compensation-related transactions. On September 1, 2026, he acquired 130 shares of common stock under a purchase plan at $113.38 per share and received an additional 130 shares of restricted stock awards that carry a one-year cliff vesting condition tied to continued beneficial ownership of the purchase-plan shares. On September 2, 2026, 72 shares of common stock were withheld by the company at a price based on the September 1 closing price of $113.38 to satisfy tax withholding obligations from vesting restricted stock units; no Rule 10b5-1 trading plan is reported.
CORCEPT THERAPEUTICS INC (CORT) reports the initial equity holdings of Roberto Wandenkolk Vieira, who serves as President, Oncology. He directly holds 4,068 shares of Common Stock, including unvested restricted stock awards, and three option grants to purchase up to 480,000 shares of Common Stock at exercise prices of $21.63, $60.58 and $35.70 with expirations in 2034, 2035 and 2036.
CORCEPT THERAPEUTICS INC (CORT) has a notice of proposed sale under Rule 144 for up to 75,295 shares of common stock for the account of officer Roberto Wandenkolk Vieira, to be sold through Stifel Nicolaus & Company Inc. The shares include 74,999 acquired through a stock option exercise on February 1, 2024 and 296 acquired through an ESPP purchase on September 1, 2026. The notice cites an aggregate market value of $8,339,418 and 108,098,397 shares of common stock outstanding, with an approximate sale date of September 2, 2026.
For CORCEPT THERAPEUTICS INC (CORT), director Kimberly Park reported an option exercise and related share dispositions on August 26, 2026. She exercised 30,000 stock options to acquire 30,000 shares of common stock at an exercise price of $13.49 per share, from a grant that is described as fully exercisable and expires on September 17, 2029. To fund the exercise, 3,315 shares of common stock were withheld by the issuer as payment of the exercise price, and 26,685 shares of common stock were sold at a weighted average price of $122.5471 per share, with actual sale prices ranging from $122.50 to $122.80. After this transaction, 30,000 stock options remain reported as directly owned.
CORCEPT THERAPEUTICS INC (CORT) officer Sean Maduck reported an option exercise and related sales on August 25, 2026. He exercised 30,955 options at an exercise price of $11.35 per share, fully exercisable, and received 30,955 shares of common stock, then sold all 30,955 shares in open-market transactions at weighted average prices around $125–126 per share under a Rule 10b5-1 trading plan adopted on December 8, 2025. Following the option exercise, 169,045 options of the same award type remained outstanding.
Corcept Therapeutics Incorporated (CORT) received a Rule 144 notice from director Kimberly Park regarding a planned sale of common stock. The notice covers 26,685 shares of Corcept common stock to be sold through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $3,270,169.36, based on an issuer share count of 108,098,397 shares. The proposed sale date and related stock option exercise are listed as 08/26/2026, with cash payment for the option exercise and trading on NASDAQ.